Beyza Yılmaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Beyza Yılmaz has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Ayyub Ebrahimi
Molecular Biology and Genetics Haliç University Istanbul Turkey
1 shared publication - Basak Dalbayrak
Institute of Biotechnology, Gebze Technical University, Gebze, 41400, Kocaeli, Türkiye
1 shared publication - Elif Damla Arisan
Institute of Biotechnology, Gebze Technical University, Gebze, 41400, Kocaeli, Türkiye
1 shared publication - Elif Ozkok
Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
1 shared publication - Elif Yorulmaz
Department of Gastroenterology University of Health Sciences Bağcılar Training and Research Hospital Istanbul Turkey
1 shared publication - Erdem Sünger
Department of Medical Oncology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34214, Turkey
1 shared publication
Latest Publications
- Open Access
- 17 June 2026
- Published by Wiley in Experimental Physiology
Timing‐dependent protective and therapeutic effects of ethyl pyruvate in trinitrobenzene sulfonic acid‐induced experimental colitis
Ulcerative colitis (UC) involves excessive inflammation, extracellular matrix remodelling and oxidative stress. Ethyl pyruvate (EP) exhibits anti‐inflammatory effects, but the comparative efficacy of prophylactic versus therapeutic administration and timing‐dependent molecular responses remains unclear. The objective of this work was to evaluate timing‐dependent protective and therapeutic effects of EP in trinitrobenzene sulfonic acid (TNBS)‐induced experimental colitis, focusing on inflammatory mediators, matrix metalloproteinases (MMPs), oxidative status and gene expression. Rats were randomly assigned to Control, EP, Colitis, Pre‐colitis (EP before TNBS) and Post‐colitis (EP after TNBS) groups. Colonic injury was assessed macroscopically and histopathologically. Tissue levels of matrix metalloproteinase (MMP)‐2, MMP‐9, interleukin (IL)‐1, IL‐17, IL‐10, nuclear factor‐κB (NF‐κB), inducible nitric oxide synthase (iNOS) and total antioxidant capacity (TAC) were measured using ELISA kits. Gene expression of MMP‐9, cytokines, NF‐κB, high mobility group box 1 (HMGB1), iNOS and interferon‐γ was analysed by quantitative real‐time PCR. TNBS induced severe colonic injury with upregulation of pro‐inflammatory cytokines, NF‐κB signalling, MMP‐2/9 and oxidative imbalance ( P < 0.01). EP attenuated tissue damage in both prophylactic and therapeutic settings. Post‐colitis (therapeutic) EP administration produced greater suppression of MMP‐2, MMP‐9, NF‐κB, HMGB1 and iNOS, along with superior restoration of TAC ( P < 0.05), indicating timing‐dependent modulation of inflammatory and matrix degradation pathways. EP exerts both preventive and therapeutic effects in TNBS‐induced colitis by suppressing inflammatory signalling, regulating extracellular matrix remodelling and enhancing antioxidant defences. Therapeutic administration is more effective than prophylactic treatment, highlighting the importance of timing in optimizing EP's efficacy in inflammatory bowel disease.
- 17 June 2026
- Published by Wiley in Experimental Physiology
Open AccessTiming‐dependent protective and therapeutic effects of ethyl pyruvate in trinitrobenzene sulfonic acid‐induced experimental colitis
Ulcerative colitis (UC) involves excessive inflammation, extracellular matrix remodelling and oxidative stress. Ethyl pyruvate (EP) exhibits anti‐inflammatory effects, but the comparative efficacy of prophylactic versus therapeutic administration and timing‐dependent molecular responses remains unclear. The objective of this work was to evaluate timing‐dependent protective and therapeutic effects of EP in trinitrobenzene sulfonic acid (TNBS)‐induced experimental colitis, focusing on inflammatory mediators, matrix metalloproteinases (MMPs), oxidative status and gene expression. Rats were randomly assigned to Control, EP, Colitis, Pre‐colitis (EP before TNBS) and Post‐colitis (EP after TNBS) groups. Colonic injury was assessed macroscopically and histopathologically. Tissue levels of matrix metalloproteinase (MMP)‐2, MMP‐9, interleukin (IL)‐1, IL‐17, IL‐10, nuclear factor‐κB (NF‐κB), inducible nitric oxide synthase (iNOS) and total antioxidant capacity (TAC) were measured using ELISA kits. Gene expression of MMP‐9, cytokines, NF‐κB, high mobility group box 1 (HMGB1), iNOS and interferon‐γ was analysed by quantitative real‐time PCR. TNBS induced severe colonic injury with upregulation of pro‐inflammatory cytokines, NF‐κB signalling, MMP‐2/9 and oxidative imbalance ( P < 0.01). EP attenuated tissue damage in both prophylactic and therapeutic settings. Post‐colitis (therapeutic) EP administration produced greater suppression of MMP‐2, MMP‐9, NF‐κB, HMGB1 and iNOS, along with superior restoration of TAC ( P < 0.05), indicating timing‐dependent modulation of inflammatory and matrix degradation pathways. EP exerts both preventive and therapeutic effects in TNBS‐induced colitis by suppressing inflammatory signalling, regulating extracellular matrix remodelling and enhancing antioxidant defences. Therapeutic administration is more effective than prophylactic treatment, highlighting the importance of timing in optimizing EP's efficacy in inflammatory bowel disease.
- Open Access
- 1 January 2025
- Published by Wiley in Scientifica
- Vol. 2025 (1)
Boron‐Enhanced Mitochondrial Repair: DeepA‐I Tissue Regeneration
Cellular metabolism is a key regulator of tissue repair and regeneration, with mitochondrial function playing a central role in energy production and cellular homeostasis. Dysfunctional mitochondria, often due to excessive reactive oxygen species (ROS), contribute to oxidative stress, impaired wound healing, and chronic inflammation. This study investigates the therapeutic potential of DeepA‐I, a Boron‐enriched compound, in enhancing mitochondrial health, reducing oxidative damage, and promoting cellular repair in human umbilical vein endothelial cells (HUVEC) and mouse embryonic fibroblasts (MEF). Boron quantification via inductively coupled plasma optical emission spectroscopy (ICP‐OES) confirmed its presence in DeepA‐I. Cytotoxicity assessment (MTT assay) demonstrated its safety, while fluorescence microscopy (DAPI, MitoSPY, DCFDA) revealed reduced ROS levels and preserved mitochondrial integrity. A scratch assay showed accelerated cell migration and wound closure in DeepA‐I‐treated cells. Western blot analysis indicated the downregulation of Akt (a proliferation marker) and the upregulation of NRF2, a key regulator of oxidative stress resistance, without affecting apoptosis‐related proteins. These results suggest that DeepA‐I, via its Boron‐mediated mechanisms, enhances mitochondrial function, mitigates ROS‐induced damage, and improves tissue repair, positioning it as a promising therapeutic candidate for inflammatory and degenerative conditions.
- 1 January 2025
- Published by Wiley in Scientifica
- Vol. 2025 (1)
Open AccessBoron‐Enhanced Mitochondrial Repair: DeepA‐I Tissue Regeneration
Cellular metabolism is a key regulator of tissue repair and regeneration, with mitochondrial function playing a central role in energy production and cellular homeostasis. Dysfunctional mitochondria, often due to excessive reactive oxygen species (ROS), contribute to oxidative stress, impaired wound healing, and chronic inflammation. This study investigates the therapeutic potential of DeepA‐I, a Boron‐enriched compound, in enhancing mitochondrial health, reducing oxidative damage, and promoting cellular repair in human umbilical vein endothelial cells (HUVEC) and mouse embryonic fibroblasts (MEF). Boron quantification via inductively coupled plasma optical emission spectroscopy (ICP‐OES) confirmed its presence in DeepA‐I. Cytotoxicity assessment (MTT assay) demonstrated its safety, while fluorescence microscopy (DAPI, MitoSPY, DCFDA) revealed reduced ROS levels and preserved mitochondrial integrity. A scratch assay showed accelerated cell migration and wound closure in DeepA‐I‐treated cells. Western blot analysis indicated the downregulation of Akt (a proliferation marker) and the upregulation of NRF2, a key regulator of oxidative stress resistance, without affecting apoptosis‐related proteins. These results suggest that DeepA‐I, via its Boron‐mediated mechanisms, enhances mitochondrial function, mitigates ROS‐induced damage, and improves tissue repair, positioning it as a promising therapeutic candidate for inflammatory and degenerative conditions.